SRNE - Sorrento's license partner submits socazolimab NDA in China for cervical cancer

Sorrento Therapeutics (NASDAQ:SRNE) license partner China Oncology Focus has submitted a new drug application for socazolimab for the greater China territory to treat recurrent or metastatic cervical cancer. China Oncology Focus is an affiliate of Lee's Pharmaceutical Holdings. Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform. In February 2021, Sorrento and Lee’s Pharma announced that socazolimab had been granted breakthrough designation by the NMPA. Lee’s Pharma is a research-driven biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in Greater China. Sorrento shares up marginally premarket.

For further details see:

Sorrento’s license partner submits socazolimab NDA in China for cervical cancer